ESR1 and breast carcinoma: AMP was also validated in their study and applied to cohorts of (1) 110 of early-stage and advanced ER+ breast cancer patients (Clinical Genotyping Cohort) and (2) 63 of advanced ER+ breast cancer patients with matched primary and metastatic samples (Matched Primary/Metastasis Cohort).